
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
Deanna J. Attai, MD, assistant clinical professor, Department of Surgery, UCLA, discusses breast cancer survivor support and education on Twitter.
Deanna J. Attai, MD, assistant clinical professor, Department of Surgery, UCLA, discusses breast cancer survivor support and education on Twitter.
<<<






